Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has reported its first quarter financial results for the period ending March 31, ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.

The U.S. Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ drug product manufacturing hub in ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, described markets as "fragile," citing sentiment and presidential influence. She highlighted Royalty Pharma as a ...

How CDMOs are reshaping pharmaceutical partnerships through friendshoring, risk-sharing economics, and specialized development capabilities.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

BofA raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $41 and keeps a Buy rating on the shares. The firm, in its preview of ...

Ligand Pharmaceuticals offers biotech exposure with reduced risk through its royalty platform. Discover why its valuation now ...